Frontier Biotechnologies Signs Licensing Deal With GlaxoSmithKline; Shares Jump 9%
MT Newswires Live
Feb 24
Frontier Biotechnologies (SHA:688221) signed an exclusive worldwide licensing agreement with GlaxoSmithKline for two early-stage siRNA assets, securing an upfront payment of $40 million and a near-term milestone payment of $13 million.
The company is also eligible for additional payments of up to $950 million across the two programs, according to a Tuesday filing with the Shanghai bourse.
Under the deal, Frontier will advance a Phase I trial in China for one candidate and complete investigational new drug-enabling studies for another. GlaxoSmithKline takes over all subsequent clinical development, regulator submissions and commercialization works.
Shares of the biotechnology company rose 9% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.